Ibrutinib Significantly Inhibited Bruton's Tyrosine Kinase (BTK) Phosphorylation, In-Vitro Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model

Authors

Gaurav Nayyar, New York Medical College
Yaya Chu, New York Medical CollegeFollow
Tishi Shah, New York Medical College
Matthew Barth
Rodney R. Miles
Janet Ayello, New York Medical CollegeFollow
Erin Morris
Lauren Harrison, New York Medical CollegeFollow
Carmella van de Ven, New York Medical CollegeFollow
Paul Galardy
Stanton C. Goldman
Megan S. Lim
Michelle Hermiston
Linda M. McAllister-Lucas
Lisa Giulino-Roth
Sherrie L. Perkins
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty, Resident/Fellow

Document Type

Abstract

Publication Date

9-2018

Journal Title

British Journal of Haematology

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Nayyar, G., Chu, Y., Shah, T., Barth, M., Miles, R. R., Ayello, J., Morris, E., Harrison, L., van de Ven, C., Galardy, P., Goldman, S. C., Lim, M. S., Hermiston, M., McAllister-Lucas, L. M., Giulino-Roth, L., Perkins, S. L., & Cairo, M. S. (2018). Ibrutinib Significantly Inhibited Bruton's Tyrosine Kinase (BTK) Phosphorylation, In-Vitro Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model. British Journal of Haematology, 182 (Suppl. 1), 37-38. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/375